Takeda leads Asia's acquisitive charge in 2012/13
This article was originally published in Scrip
Executive Summary
Out of a total of 19 corporate acquisition or financing deals completed in Asia over the April 2012-March 2013 period, it comes as no surprise to see Asia's largest homegrown pharma firm, Japan's Takeda, take home the prize for sheer number of transactions.
You may also be interested in...
Japan Tirabrutinib Approval Breaks New BTK Ground In Lymphoma
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Japan Enhertu Nod Another Boost For Daiichi's Oncology Hopes
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
GTS Alliance Gives Mochida A Cell Therapy Buy-In
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
Need a specific report? 1000+ reports available
Buy Reports